---
document_datetime: 2025-12-29 08:36:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vantobra.html
document_name: vantobra.html
version: success
processing_time: 0.0919634
conversion_datetime: 2025-12-31 03:14:27.042969
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vantobra

[RSS](/en/individual-human-medicine.xml/65855)

##### Withdrawn

This medicine's authorisation has been withdrawn

tobramycin Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vantobra](#news-on)
- [More information on Vantobra](#more-information-on-vantobra-539)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 February 2019, the European Commission withdrew the marketing authorisation for Vantobra (tobramycin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, PARI Pharma GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Vantobra was granted marketing authorisation in the EU on 18 March 2015 for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis. The marketing authorisation was initially valid for a 5-year period. Vantobra is an identical product to Tobramycin PARI, which is authorised in the EU for the same condition.

The European Public Assessment Report (EPAR) for Vantobra is updated to reflect the fact that the marketing authorisation is no longer valid.

Vantobra : EPAR - Summary for the public

Reference Number: EMA/169512/2015

English (EN) (543.33 KB - PDF)

**First published:** 19/03/2015

**Last updated:** 29/03/2019

[View](/en/documents/overview/vantobra-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-711)

български (BG) (626.87 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/bg/documents/overview/vantobra-epar-summary-public_bg.pdf)

español (ES) (542.06 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/es/documents/overview/vantobra-epar-summary-public_es.pdf)

čeština (CS) (606.64 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/cs/documents/overview/vantobra-epar-summary-public_cs.pdf)

dansk (DA) (542.61 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/da/documents/overview/vantobra-epar-summary-public_da.pdf)

Deutsch (DE) (544.04 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/de/documents/overview/vantobra-epar-summary-public_de.pdf)

eesti keel (ET) (544.87 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/et/documents/overview/vantobra-epar-summary-public_et.pdf)

ελληνικά (EL) (630.6 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/el/documents/overview/vantobra-epar-summary-public_el.pdf)

français (FR) (543.28 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/fr/documents/overview/vantobra-epar-summary-public_fr.pdf)

hrvatski (HR) (564.42 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/hr/documents/overview/vantobra-epar-summary-public_hr.pdf)

italiano (IT) (544.71 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/it/documents/overview/vantobra-epar-summary-public_it.pdf)

latviešu valoda (LV) (604.24 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/lv/documents/overview/vantobra-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (566.91 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/lt/documents/overview/vantobra-epar-summary-public_lt.pdf)

magyar (HU) (602.93 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/hu/documents/overview/vantobra-epar-summary-public_hu.pdf)

Malti (MT) (609.65 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/mt/documents/overview/vantobra-epar-summary-public_mt.pdf)

Nederlands (NL) (547.25 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/nl/documents/overview/vantobra-epar-summary-public_nl.pdf)

polski (PL) (607.26 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/pl/documents/overview/vantobra-epar-summary-public_pl.pdf)

português (PT) (547.78 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/pt/documents/overview/vantobra-epar-summary-public_pt.pdf)

română (RO) (566.62 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/ro/documents/overview/vantobra-epar-summary-public_ro.pdf)

slovenčina (SK) (605.91 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/sk/documents/overview/vantobra-epar-summary-public_sk.pdf)

slovenščina (SL) (598.41 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/sl/documents/overview/vantobra-epar-summary-public_sl.pdf)

Suomi (FI) (540.13 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/fi/documents/overview/vantobra-epar-summary-public_fi.pdf)

svenska (SV) (541.79 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/sv/documents/overview/vantobra-epar-summary-public_sv.pdf)

Vantobra : EPAR - Risk-management-plan summary

Reference Number: EMA/169513/2015

English (EN) (578.05 KB - PDF)

**First published:** 19/03/2015

**Last updated:** 29/03/2019

[View](/en/documents/rmp-summary/vantobra-epar-risk-management-plan-summary_en.pdf)

## Product information

Vantobra : EPAR - Product Information

English (EN) (773.19 KB - PDF)

**First published:** 19/03/2015

**Last updated:** 29/03/2019

[View](/en/documents/product-information/no-longer-authorised-vantobra-epar-product-information_en.pdf)

**Latest procedure affecting product information:** N/0010 21/09/2017

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vantobra : EPAR - All Authorised presentations

English (EN) (474.54 KB - PDF)

**First published:** 19/03/2015

**Last updated:** 29/03/2019

[View](/en/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-905)

български (BG) (515.54 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/bg/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_bg.pdf)

español (ES) (474.28 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/es/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_es.pdf)

čeština (CS) (504.15 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/cs/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (476.85 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/da/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (476.66 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/de/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (488.49 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/et/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (510.86 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/el/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_el.pdf)

français (FR) (474.01 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/fr/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (479.67 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/hr/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (473.89 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/is/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_is.pdf)

italiano (IT) (476.77 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/it/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (505.07 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/lv/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (489.11 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/lt/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (495.44 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/hu/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (505.29 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/mt/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (473.49 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/nl/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (473.56 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/no/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_no.pdf)

polski (PL) (502.07 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/pl/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_pl.pdf)

português (PT) (473.98 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/pt/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_pt.pdf)

română (RO) (489.95 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/ro/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (504.65 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/sk/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (499 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/sl/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (476.15 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/fi/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (473.59 KB - PDF)

**First published:**

19/03/2015

**Last updated:**

29/03/2019

[View](/sv/documents/all-authorised-presentations/vantobra-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vantobra Active substance tobramycin International non-proprietary name (INN) or common name tobramycin Therapeutic area (MeSH)

- Cystic Fibrosis
- Respiratory Tract Infections

Anatomical therapeutic chemical (ATC) code J01GB01

### Pharmacotherapeutic group

- Antibacterials for systemic use
- Aminoglycoside antibacterials

### Therapeutic indication

Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/002633 Marketing authorisation holder

Pari Pharma GmbH

Moosstrasse 3

Marketing authorisation issued 18/03/2015 Withdrawal of marketing authorisation 18/02/2019 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vantobra : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (560.49 KB - PDF)

**First published:** 15/12/2015

**Last updated:** 29/03/2019

[View](/en/documents/procedural-steps-after/vantobra-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Vantobra : EPAR - Public assessment report

Adopted

Reference Number: EMA/86872/2015

English (EN) (2.81 MB - PDF)

**First published:** 19/03/2015

**Last updated:** 29/03/2019

[View](/en/documents/assessment-report/vantobra-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vantobra

Adopted

Reference Number: EMA/CHMP/780275/2014

English (EN) (554.55 KB - PDF)

**First published:** 03/06/2014

**Last updated:** 29/03/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vantobra_en.pdf)

#### News on Vantobra

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 June 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-june-2014) 27/06/2014

#### More information on Vantobra

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu309613) on 27 February 2009. Vantobra was withdrawn from the Community register of orphan medicinal products in June 2014 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

**This page was last updated on** 29/03/2019

## Share this page

[Back to top](#main-content)